Concord Biotech financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹309cr+25.1% on Q2 FY26
Net profit
₹69.6cr+10.3% on Q2 FY26
EBITDA margin
33.8%−2.0 pts on Q2 FY26
EPS
₹6.65+10.3% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue309247+25.1%
EBITDA10488.5+18.0%
EBITDA margin33.8%35.8%−2.0 pts
Profit before tax96.183.4+15.3%
Net profit69.663.1+10.3%
EPS₹6.65₹6.03+10.3%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹309 crNet profit₹69.6 crNet margin22.5%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024
13,271———
446414317259
−3.9−1.90.0—
0.00.00.46.2
12,821———
1,1701,0551,2001,017
—−12.1%+18.0%—
404367506432
34.5%34.8%42.2%42.4%
330293452378
279259372308
23.9%24.6%31.0%30.3%
₹27.00₹24.94₹35.52₹29.45
—−29.8%+20.6%—
—267245265
—−95.2−111−85.7
172172133180
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CONCORDBIO₹1,268.50

Concord Biotech Ltd.

· Pharma & Health
₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹13,271 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————13,270.5
- Cash, Equiv & ST Investments—258.8317.4414.2445.6
+ Minority Interest——0.0-1.9-3.9
+ Total Debt—6.20.40.00.0
Enterprise Value————12,821.0
Revenue—1,016.91,200.11,054.91,170.4
Growth %, YoY——+18.0-12.1—
EBITDA—431.6506.3367.4404.3
Margin %—42.4442.1934.8334.54
EBIT—378.0452.0292.9329.5
Net Income—308.1371.6259.2279.4
Margin %—30.3030.9724.5723.87
EPS, Adj (current shares)—29.4535.5224.9427.00
Growth %, YoY——+20.6-29.8—
Cash from Operations—265.5244.5266.9—
Capital Expenditures—-85.7-111.2-95.2—
Free Cash Flow—179.8133.3171.7171.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Concord Biotech financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Concord Biotech (NSE: CONCORDBIO) had a market capitalisation of ₹12,874 crore at the 29 October 2026 close (₹1,230.60 a share), a PE ratio of 45.6 on the last four quarters' profit and a price-to-book ratio of 6.20. In FY26 its consolidated net profit attributable to shareholders was ₹261 crore on revenue of ₹1,055 crore; in Q2 FY27 (July–September 2026) it was ₹70.7 crore, up 11.1% year on year. It had no borrowings on 30 September 2026. Promoters held 44.09% of the shares on 30 September 2026.

Concord Biotech Q2 FY27 results
filed 27 October 2026
Share price used
₹1,230.60 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Concord Biotech at a glance · consolidated

Market cap
₹12,874 Crat ₹1,230.60 · 29 Oct close
PE ratio (last 4 quarters)
45.649.3 on FY26 profit
Price to book (PB)
6.20book value ₹198.42 a share
ROE (FY26)
13.6%−8.6 pts vs FY25ROCE 15.0%
Debt to equity
0.00net cash ₹446 Cr
Promoter holding
44.09%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.61%₹7.55 a share in 12 months
Net worth
₹2,076 Cr+13.6% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹172 Cr+28.8% vs FY25

Questions

What is the Concord Biotech PE ratio today?

Concord Biotech's PE ratio is 45.6 at the 29 October 2026 close (₹1,230.60 a share): a market capitalisation of ₹12,874 crore divided by consolidated net profit attributable to shareholders of ₹282 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit attributable to shareholders (₹261 crore) it is 49.3.

What is the Concord Biotech net worth?

Concord Biotech's net worth — shareholders' equity in its consolidated balance sheet — was ₹2,076 crore on 30 September 2026, up 13.6% from ₹1,827 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹12,874 crore at the 29 October 2026 close.

What is the Concord Biotech book value per share?

Concord Biotech's book value per share was ₹198.42 on 30 September 2026: shareholders' equity of ₹2,076 crore divided by the 10.46 crore shares in issue, up 13.6% from ₹174.68 a year earlier. The share price at the 29 October 2026 close was ₹1,230.60.

What is the Concord Biotech PB ratio (price to book value)?

Concord Biotech's price-to-book (PB) ratio is 6.20 at the 29 October 2026 close: a market capitalisation of ₹12,874 crore divided by shareholders' equity (book value) of ₹2,076 crore on 30 September 2026. That is a book value of ₹198.42 per share against a share price of ₹1,230.60.

What is the Concord Biotech debt to equity ratio?

Concord Biotech's debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹2,072 crore. A year earlier, on 30 September 2025, it was 0.00.

What is the Concord Biotech ROE and ROCE?

In FY26, Concord Biotech's return on equity (ROE) was 13.6% and its return on capital employed (ROCE) was 15.0%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 22.3% and ROCE 26.5%.

What is the Concord Biotech market cap?

Concord Biotech's market capitalisation was ₹12,874 crore at the 29 October 2026 close: 10.46 crore shares at ₹1,230.60 each.

Is Concord Biotech debt free?

Yes. Concord Biotech had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹446 crore of cash, bank balances and current investments.

What is the Concord Biotech EPS?

Concord Biotech's basic earnings per share (EPS) were ₹24.78 in FY26, against ₹35.52 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹26.71.

What is the Concord Biotech dividend yield?

Concord Biotech's dividend yield is 0.61% at the 29 October 2026 close: dividends of ₹7.55 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,230.60. They were ₹7.55 on 24 July 2026.

What is the Concord Biotech promoter holding?

Promoters held 44.09% of Concord Biotech on 30 September 2026, up 0.01 percentage points from 44.08% the previous quarter and up 0.01 percentage points from 44.08% a year earlier, according to the shareholding pattern filed with NSE.

What is the Concord Biotech free cash flow?

In FY26, Concord Biotech generated ₹267 crore of cash from operations and spent ₹95.2 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹172 crore. In FY25 it was ₹133 crore.

What is the Concord Biotech dividend in 2026 and its record date?

In 2026, Concord Biotech has declared one dividend: ₹7.55 with record date 24 July 2026.

What is the Concord Biotech revenue and profit in FY26?

In FY26 (April 2025–March 2026), Concord Biotech's consolidated net profit attributable to shareholders was ₹261 crore, down 29.8% from ₹372 crore in FY25, on revenue from operations of ₹1,055 crore (down 12.1%).

When are the Concord Biotech next results?

Concord Biotech has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

What is the Concord Biotech shareholding pattern?

On 30 September 2026, Concord Biotech's shares were held by promoters 44.09%, foreign portfolio investors (FII/FPI) 7.28%, domestic institutions (DII) 10.95% (including mutual funds at 5.84%) and retail and other non-institutional investors 37.68%. Over the year, FII holding was down 0.75 percentage points from 8.03% and DII holding was up 1.40 percentage points from 9.55%.

How does Concord Biotech compare with its peers?

On FY26 consolidated figures, against Biocon, Divi's Labs and Caplin Point Laboratories: Concord Biotech's operating margin of 27.8% is the third highest of the four (Biocon 8.9%, Divi's Labs 28.2%, Caplin Point Laboratories 31.5%; peer average 22.8%); its return on equity of 13.6% is the third highest of the four (Biocon 1.4%, Divi's Labs 16.2%, Caplin Point Laboratories 19.9%; peer average 12.5%).

How does the Concord Biotech PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Concord Biotech's PE ratio is 49.3, the third highest of the four: Biocon 148.7, Divi's Labs 99.7 and Caplin Point Laboratories 28.2, a peer average of 92.2. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What are the Concord Biotech latest quarterly results?

Concord Biotech's latest results are for Q2 FY27 (July–September 2026), filed on 27 October 2026: consolidated net profit attributable to shareholders ₹70.7 crore, up 11.1% from ₹63.6 crore in Q2 FY26; revenue from operations ₹309 crore, up 25.1% year on year.

Concord Biotech vs Biocon: how do they compare?

In FY26, Concord Biotech earned net profit attributable to shareholders of ₹261 crore on revenue of ₹1,055 crore, against ₹386 crore on ₹16,927 crore for Biocon. Concord Biotech's operating margin was 27.8% (Biocon 8.9%) and its return on equity 13.6% (Biocon 1.4%). At the 29 October 2026 close, Concord Biotech's market capitalisation was ₹12,874 crore against ₹57,346 crore for Biocon, and its PE ratio on FY26 profit 49.3 against 148.7.

Where do these Concord Biotech figures come from?

From Concord Biotech's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.